RLD2202

RLD2202 is a small molecule drug developed by Hanmi Pharmaceutical. It has been studied in Phase 1 clinical trials, primarily as a component of combination therapies (notably with RLD2203) and as part of the fixed-dose combination HCP2202. The main focus of these studies has been to evaluate pharmacokinetics, pharmacodynamics, safety, and drug-drug interactions in healthy volunteers. While the precise mechanism of action and therapeutic targets for RLD2202 have not been publicly disclosed, it is under investigation for potential use in cardiovascular disorders, gastric ulcers, and duodenal ulcers as part of combination regimens[1][5][9]. As of June 2025, no active indications or approvals are reported.